Detalus Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.05M Buy
872
+28
+3% +$28.6K 0.2% 58
2026
Q1
$776K Sell
844
-3
-0.4% -$3.04K 0.18% 68
2025
Q4
$910K Hold
847
0.22% 59
2025
Q3
$646K Buy
847
+9
+1% +$6.7K 0.17% 72
2025
Q2
$654K Sell
838
-7
-0.8% -$5.44K 0.19% 69
2025
Q1
$698K Buy
845
+37
+5% +$30.8K 0.22% 64
2024
Q4
$624K Buy
808
+10
+1% +$8.28K 0.21% 67
2024
Q3
$707K Buy
798
+13
+2% +$11.7K 0.24% 55
2024
Q2
$711K Buy
785
+256
+48% +$205K 0.24% 55
2024
Q1
$412K Hold
529
0.15% 90
2023
Q4
$308K Sell
529
-62
-10% -$36.2K 0.12% 103
2023
Q3
$317K Hold
591
0.15% 91
2023
Q2
$277K Hold
591
0.12% 109
2023
Q1
$203K Sell
591
-89
-13% -$30K 0.1% 130
2022
Q4
$249K Buy
+680
New +$241K 0.12% 114
2022
Q3
Sell
-741
Closed -$240K 131
2022
Q2
$240K Hold
741
0.14% 101
2022
Q1
$212K Sell
741
-100
-12% -$25.7K 0.11% 101
2021
Q4
$232K Buy
+841
New +$213K 0.11% 108

Other funds holding LLY

Detalus Advisors's LLY Position: Q2 2026 in Review

Detalus Advisors increased its Eli Lilly (LLY) stake by 3.3% in Q2 2026, buying an estimated $28.6K and bringing the position to 872 shares worth $1.05M. The position accounts for 0.2% of the portfolio, ranked #58.

Detalus Advisors first reported a position in LLY in Q4 2021 and has held it in 18 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Detalus Advisors held 872 shares of Eli Lilly worth $1.05M as of Q2 2026.
  • Detalus Advisors bought 28 Eli Lilly shares in Q2 2026, an estimated $28.6K.
  • Eli Lilly made up 0.2% of Detalus Advisors's portfolio in Q2 2026, its #58 holding.
  • Detalus Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 18 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Detalus Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.